RecruitingNCT06559033

Determine the Frequency of Variants in the GBA/PSAP Genes in Patients With MM or MGUS

Determine the Frequency of Variants in the GBA/PSAP Genes in Patients With Multiple Myeloma (MM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)

Sponsor

University Hospital, Rouen

Enrollment

300 participants

Start Date

Oct 7, 2025

Study Type

OBSERVATIONAL

Conditions

Monoclonal Gammopathy of Undetermined Significance Myeloma, Multiple

Summary

No effective specific treatment is currently available for the management of Multiple Myeloma (MM) and Monoclonal Gammopathy of Undetermined Significance (MGUS). A better understanding of the pathophysiological mechanisms would make it possible to propose treatments specifically targeting the deregulated pathways.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called Evaluation of the presence and number of mutated alleles of the GBA/PSAP genes in patients with MM or MGUS for people with monoclonal gammopathy of undetermined significance and myeloma, multiple. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALEvaluation of the presence and number of mutated alleles of the GBA/PSAP genes in patients with MM or MGUS

Estimation of the frequency of variants in the PSAP/GBA genes in patients with MM or MGUS, then comparison with a reference frequency from databases such as the Exome Aggregation Consortium, the Exome Sequencing Project, the 1000 Genomes Project and the dbSNP.